[Palivizumab: four seasons in Russia].

In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data.

[Adaptation of the circulatory system of newborn infants with intrauterine hypotrophy].

A study was made of adaptation of the circulatory system in 40 full-term newborns with grade II and III intrauterine++ hypotrophy during the early neonatal period. Analysis of the hemodynamics demonstrated the study group children to have arterial hypertension, BP lability, and high peripheral vascular resistance. The conclusion has been made about the necessity of classifying intrauterine hypotrophy newborns with the group at risk for adaptation failure in the circulatory system.